Buprenorphine Transdermal Patch and Mitotane: Interaction Details

Brand names
Mitotane
Lysodren
Buprenorphine Transdermal Patch
ButransBelbucaSublocade +2 more
Same medicines, other forms
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page

A close look at the Buprenorphine Transdermal Patch and Mitotane interaction:

Share

Share this interaction

Buprenorphine Transdermal Patch

Brand names
  • Butrans
  • Belbuca
  • Sublocade
  • Buprenex
  • Brixadi

What Happens When You Take Buprenorphine Transdermal Patch With Mitotane

What can happen when they are taken together (rated Major)

Reduced buprenorphine exposure and reduced of buprenorphine

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Giving buprenorphine together with a can lower buprenorphine , which may lead to withdrawal symptoms. When a patient on buprenorphine needs a CYP3A4 inducer, a higher buprenorphine dose can be considered until the drug effects are stable, with monitoring for withdrawal.

Conversely, if the CYP3A4 inducer is stopped in a patient on buprenorphine, consider lowering the buprenorphine dose and monitor for .2 Should the dose be impossible to adjust once the inducer is no longer given, return the patient to a buprenorphine formulation that allows finer dose adjustments.

For patients switched from transmucosal buprenorphine taken with CYP3A4 , check that the plasma buprenorphine level achieved with subQ buprenorphine is sufficient. Patients already receiving subQ buprenorphine who then need a CYP3A4 inducer should be monitored for withdrawal.

If the buprenorphine dose proves inadequate while the drug is present, and that drug cannot be reduced or stopped, the buprenorphine dose should be adjusted. When the available doses cannot reach the desired dose, treat the patient with a buprenorphine formulation that allows more precise dose adjustments.1

The Buprenorphine Transdermal Patch and Mitotane Interaction, Explained

Mitotane can make your buprenorphine patch work less well. Mitotane speeds up an enzyme in the liver () that breaks down buprenorphine, so less of the pain medicine stays in your body. This could bring back pain or cause withdrawal symptoms such as restlessness, sweating, nausea, or achiness.

Also, if mitotane is later stopped, buprenorphine levels can climb back up, which raises the chance of drowsiness or slowed breathing. Please keep using both as prescribed and tell your pharmacist or doctor about any pain changes or withdrawal-like symptoms. Your care team can manage this by adjusting your dose and checking on you more closely.

Mechanism: Mitotane is a . Buprenorphine is cleared mainly by CYP3A4 (N-dealkylation to norbuprenorphine), so lowers buprenorphine exposure (reduced and ) and may reduce analgesic . Direction: decreased drug effect. Onset unspecified; evidence rated probable; severity major.

  • Risk: subtherapeutic exposure and withdrawal.
  • If an inducer is necessary, consider increasing the buprenorphine dose until stable effects are achieved, and monitor for withdrawal.
  • On inducer discontinuation, consider a dose reduction and monitor for (induction wanes slowly with mitotane).
  • If patch strengths do not allow adequate , consider a formulation permitting finer dose adjustment.

See the 2 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Buprenorphine Transdermal Patch and Mitotane Interact

The likely mechanism

of -mediated of buprenorphine

In short: Mitotane speeds up CYP3A4, an enzyme that breaks down buprenorphine, so buprenorphine can be cleared faster.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Lowers Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Buprenorphine Transdermal Patch and Mitotane Interaction

Your care team can manage this by tailoring your dose and monitoring you.

  • Keep using your patch and mitotane exactly as prescribed. Do not change either on your own.
  • Your team may increase your buprenorphine dose until your symptoms are steady, and may watch you closely for withdrawal.
  • If mitotane is stopped, your buprenorphine dose may need to be lowered, and you may be monitored for slowed breathing or unusual sleepiness.
  • If patch strengths do not allow the right dose, your prescriber may switch you to a form of buprenorphine that allows finer adjustments.

Tell your pharmacist or prescriber about returning pain, withdrawal symptoms, or excess drowsiness.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Buprenorphine Transdermal Patch or Mitotane need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: BRIXADI subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection

    The influence of a coadministered on buprenorphine exposure has not been investigated in subjects receiving subQ buprenorphine, although such interactions have been demonstrated in studies of transmucosal buprenorphine. The effects of buprenorphine may vary depending on the route of administration.1

Buprenorphine Transdermal Patch and Mitotane: Common Questions

How serious is the Buprenorphine Transdermal Patch and Mitotane interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Buprenorphine Transdermal Patch and Mitotane interaction managed?

Your care team can manage this by tailoring your dose and monitoring you. Keep using your patch and mitotane exactly as prescribed. Do not change either on your own. Your team may increase your buprenorphine dose until your symptoms are steady, and may watch you closely for withdrawal. If mitotane is stopped, your buprenorphine dose may need to be lowered, and you may be monitored for slowed breat… Management is individual — always follow your own care team's guidance.

Does taking Buprenorphine Transdermal Patch and Mitotane at different times of day help?

No. Taking them at different times of day does not prevent this one. Mitotane speeds up , an enzyme that breaks down buprenorphine, so buprenorphine can be cleared faster. That change lasts while mitotane is being taken and can continue for a while after the last dose.

Your pharmacist or prescriber can tell you how they will manage it.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Buprenorphine Transdermal Patch and Mitotane Interaction

Ask in your own words about taking Buprenorphine Transdermal Patch and Mitotane together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (2)

  1. Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
  2. Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Was this write-up helpful?

Other Serious Interactions of Buprenorphine Transdermal Patch and Mitotane

Also serious with Mitotane

Also serious with Buprenorphine Transdermal Patch

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Mitotane

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.